Moderna COVID-19 vaccine Spikevax sales to reduce amid strong competition: GlobalData
GlobalData expects Spikevax vaccine market share to decline from 30 per cent in 2022 to just 16 per cent by the end of 2028
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.